Tetratherix (ASX:TTX) has announced a significant step forward for its US-based joint venture BioOptix, with the ophthalmic biomaterials company signing a development agreement with global eye-care leader Alcon Research.
BioOptix was established by Tetratherix alongside leading ophthalmic clinicians in the United States to develop a new generation of synthetic biomaterial technologies for eye surgery and care.
Under the partnership, Alcon will provide milestone-based development funding through its corporate grant program, supporting a series of preclinical studies designed to advance BioOptix’s broad pipeline of ophthalmic biomaterial solutions. The outcomes of these studies will form a core component of future regulatory submissions and market clearances for medical devices derived from Tetratherix’s patented Tetramatrix platform.
Tetratherix CEO Will Knox said the agreement provides validation for the company’s unique technology platform, particularly given Alcon’s status as a tier-one multinational. “Securing a development funding agreement with a global tier-one leader like Alcon so early in the life of the BioOptix Joint Venture is a powerful validation of our Tetramatrix™ platform technology,” he said. “It confirms that our synthetic, bio-resorbable materials are not just theoretically advantageous but commercially desirable to the biggest players in the medical device industry.”
BioOptix is currently developing a portfolio of next-generation ophthalmic biomaterial technologies to improve surgical workflows and address unmet needs in ophthalmic care. According to the company, funding from Alcon will accelerate the commercialisation of multiple products emerging from the Tetramatrix platform.